<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087100</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0129O</org_study_id>
    <secondary_id>LILLY-H3E-US-JMGT</secondary_id>
    <secondary_id>CDR0000372921</secondary_id>
    <nct_id>NCT00087100</nct_id>
  </id_info>
  <brief_title>Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer</brief_title>
  <official_title>A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as pemetrexed disodium work in different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating&#xD;
      patients with persistent or recurrent endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor activity of pemetrexed disodium in patients with persistent or&#xD;
           recurrent endometrial adenocarcinoma that failed higher priority treatment protocols.&#xD;
&#xD;
        -  Determine the nature and degree of toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Beginning 7 days before and continuing until 3 weeks after the last dose of pemetrexed&#xD;
      disodium, patients also receive oral folic acid daily and cyanocobalamin (vitamin B_12)&#xD;
      intramuscularly every 9 weeks.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years and then every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 19-51 patients will be accrued for this study within 1-3.4&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antitumor activity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Endometrial Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed endometrial adenocarcinoma&#xD;
&#xD;
               -  Persistent or recurrent disease&#xD;
&#xD;
          -  Refractory to curative or standard therapy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable target lesion ≥ 20 mm by conventional&#xD;
                  techniques, including palpation, plain x-ray, CT scan, or MRI OR ≥ 10 mm by&#xD;
                  spiral CT scan&#xD;
&#xD;
               -  Tumors within a previously irradiated field are considered non-target lesions&#xD;
                  unless progression is documented or biopsy is obtained to confirm persistence ≥&#xD;
                  90 days after completion of radiotherapy&#xD;
&#xD;
          -  Must have received 1 prior chemotherapy regimen for endometrial cancer&#xD;
&#xD;
               -  Initial treatment may have included high-dose therapy, consolidation, or extended&#xD;
                  therapy administered after surgical or non-surgical assessment&#xD;
&#xD;
          -  Not eligible for a higher priority GOG protocol (i.e., any active phase III GOG&#xD;
             protocol for the same patient population)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  GOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN*&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN NOTE: * ≤ 5 times ULN if liver metastases are present&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 45 mL/min&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 3 months&#xD;
             after study participation&#xD;
&#xD;
          -  Neuropathy (sensory and motor) ≤ grade 1&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 weeks since prior biologic or immunologic agents for the malignant tumor&#xD;
&#xD;
          -  One prior non-cytotoxic (biologic or cytostatic) regimen for recurrent or persistent&#xD;
             disease allowed, including, but not limited to, the following:&#xD;
&#xD;
               -  Monoclonal antibodies&#xD;
&#xD;
               -  Cytokines&#xD;
&#xD;
               -  Small-molecule inhibitors of signal transduction&#xD;
&#xD;
          -  At least 24 hours since prior growth factors&#xD;
&#xD;
          -  No concurrent routine colony-stimulating factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  No more than 1 prior cytotoxic chemotherapy regimen with either single or combination&#xD;
             cytotoxic drug therapy&#xD;
&#xD;
          -  No prior pemetrexed disodium&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 1 week since prior hormonal therapy directed at the malignant tumor&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to ≥ 25% of bone marrow&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 weeks since other prior therapy directed at the malignant tumor&#xD;
&#xD;
          -  No nonsteroidal anti-inflammatory drugs 2-5 days before, during, and for 1-2 days&#xD;
             after study drug administration&#xD;
&#xD;
               -  Concurrent daily low-dose (≤ 325 mg/day) aspirin therapy allowed&#xD;
&#xD;
          -  No prior therapy that would contraindicate study participation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S. Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hinsdale Hematology Oncology Associates</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Indianapolis Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Cancer Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Regional Health Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hulston Cancer Center at Cox Medical Center South</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Cancer Center at Alamance Regional Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital Cancer Care</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214-3998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David L. Rike Cancer Center at Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake/University Ireland Cancer Center</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates - Midtown Tulsa</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosenfeld Cancer Center at Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Japan</country>
    <country>Norway</country>
  </removed_countries>
  <results_reference>
    <citation>Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky LV, Krasner CN. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol. 2009 Dec;115(3):443-6. doi: 10.1016/j.ygyno.2009.09.004. Epub 2009 Oct 4.</citation>
    <PMID>19804902</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>February 12, 2014</last_update_submitted>
  <last_update_submitted_qc>February 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>endometrial adenocarcinoma</keyword>
  <keyword>stage III endometrial carcinoma</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

